|
gptkbp:instanceOf
|
antidepressant
norepinephrine reuptake inhibitor
|
|
gptkbp:approvedBy
|
2004
|
|
gptkbp:ATCCode
|
gptkb:N06AX21
|
|
gptkbp:brand
|
gptkb:Cymbalta
Irenka
|
|
gptkbp:CASNumber
|
gptkb:136434-34-9
|
|
gptkbp:chemicalClass
|
thiophene derivative
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
uncontrolled narrow-angle glaucoma
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
delayed-release capsule
|
|
gptkbp:hasMolecularFormula
|
gptkb:C18H19NOS
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Duloxetine
|
|
gptkbp:interactsWith
|
gptkb:beer
CYP2D6 inhibitors
CYP1A2 inhibitors
other serotonergic drugs
|
|
gptkbp:IUPACName
|
(3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine
|
|
gptkbp:KEGGID
|
D07626
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
|
|
gptkbp:MedlinePlusID
|
a604030
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2013 (US)
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
60835
CHEMBL117
DB00476
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young people)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
fatigue
drowsiness
dry mouth
increased sweating
|
|
gptkbp:UNII
|
O5TNM5N07U
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder
fibromyalgia
chronic musculoskeletal pain
diabetic peripheral neuropathic pain
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|